Media Coverage


March 5, 2018
Lancet: FGF-19 agonism for NASH: a short study of a long disease (pdf)
Lancet: NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (pdf)

February 14, 2018
Nature: TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Nature: TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

February 8, 2018
Cell: LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (pdf)

February 5, 2018
Biotech Showcse™: How NGM Bio intends to build an old school biotech

Januray 25, 2018
Nature: α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling (pdf)
Nature: Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling (pdf)


December 13, 2017
Bio Century: Ghrelin’s LEAP Forward (pdf)

December 7, 2017
Science: Gut molecule that blocks ‘hunger hormone’ may spur new treatments for diabetes, anorexia

July 28, 2017
SF Business Times: Learning the hard way – NGM President Jeff Jonker Reflects on Career Lessons in Biotech (pdf)

April 25, 2017
Medpage Today: NASH Drugs Take Center Stage

Apr 24, 2017
FierceBiotech: Merck-backed NGM Bio hits its marks in midstage NASH trial

April 24, 2017
Endpoints: EASL Roundup: Bristol-Myers and NGM post a positive look at PhII NASH data; Genfit details PhIII delay

April 22, 2017
BioPharma Dive: EASL: Experimental drug slashes fatty liver markers in Phase 2


September 20, 2016
Bloomberg: Big Pharma, Biotech Attack NASH Liver Illness From All Sides

May 23, 2016
SF Business Times: Another Genentech? These are the most likely companies

May 4, 2016
PharmaLive: NGM Plans Move to Vacant Site Once Meant for Amgen

May 3, 2016
SF Business Times: Emerging biotech company preps fall takeover of never-used Amgen space


October 1, 2015
FierceBiotech: The 2015 Fierce 15 biotech execs take a bow

March 9, 2015
Nasdaq: Merck’s Partnership With NGM Is A Bold Move

March 3, 2015
BioSpace: Backed By a Genentech Alum, NGM Looks Like it Could be the Next Biotech IPO
BioPharma: Merck & Co and NGM Biopharmaceutical team to take on obesity and diabetes

February 24, 2015
WSJ: ‘We Had a Bird in the Hand, but…’ NGM Chose Merck: Rieflin Explains

February 23, 2015
Bloomberg: Merck’s Research Man Saved Biotech Deal With One Last Fat Pitch
WSJ: Merck to Team With NGM to Develop Diabetes Treatment
FierceBiotech: Merck bets big on NGM with a $450M handshake Merck Bets $450M On ‘Old School’ Biotech From NGM
Xconomy: Well-Funded NGM Bio Nabs $200M To Boost Merck’s Metabolic Pipeline


July 19, 2013
San Francisco Business Times: As biotech VC fundings rise, NGM snags $50 million

July 18, 2013
BioWorld: NGM’s Series C Garners $50M for Ongoing Work in Diabetes
FierceBiotech: NGM completes $50M Series C to advance cardio-metabolic therapies

June 25, 2013
Xconomy: NGM, Partners Seek Next Diabetes Drug Targets Among GI Tract Hormones

June 18, 2013
The Pink Sheet: MedImmune And NGM To Collaborate On Drugs To Mimic Benefits Of Bariatric Surgery (behind paywall)

June 17, 2013
PharmaTimes: AstraZeneca signs obesity and diabetes pact with NGM

May 3, 2013
SF Business Times: Diabetes drug developer NGM Biopharma, led by Genentech vets Levinson and Goeddel, raises $13.5 million


May 15, 2010
SF Business Times: NGM closes 1st tranche of $51M round